Parib 150 mg (Tablet)
Unit Price: ৳ 833.33 (1 x 120: ৳ 100,000.00)
Strip Price: ৳ 100,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Olaparib |
| Company | Drug international ltd |
| Also available as |
Indications
- Breast Cancer treatment
- Ovarian Cancer maintenance treatment
- HR-positive breast cancer treatment
- Platinum sensitive relapsed high-grade cancer treatment
Pharmacology
- Inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes
- Involvement in DNA transcription
- Cell cycle regulation
- DNA repair
- Inhibition of tumor cell growth
- Decreased tumor growth
- Potentiation of anti-tumor activity
Absorption
- Rapid absorption
- Peak plasma concentrations achieved within 1-3 hours
- No marked accumulation with multiple dosing
- Steady state exposures achieved within 3-4 days
Distribution
- Mean apparent volume of distribution at steady state of 167 ± 196 L
- Approximately 82% in vitro protein binding
Metabolism
- Metabolized primarily by CYP3A4/5 enzymes
- Oxidation reactions with subsequent conjugation
Excretion
- Mean terminal plasma half-life of 11.9 ± 4.8 hours
- Apparent plasma clearance of 8.6 ± 7.1 L/h
- 86% of dosed radioactivity recovered within 7 days
Dosage & Administration
- Recommended dose: 400 mg orally twice daily
- Total daily dose of 800 mg
- Swallow capsule whole
- Dose adjustments for adverse reactions
- Dose modifications for use with CYP3A inhibitors
- Dose modifications for patients with renal impairment
Interaction
- Potentiation and prolongation of myelosuppressive toxicity
- Drugs that increase or decrease plasma concentrations
- Avoidance of concomitant use with specific inhibitors and inducers
Contraindications
- Hypersensitivity to the drug or any ingredients in the formulation
Side Effects
- Common serious adverse reaction: anemia
- Proportion of patients discontinuing due to adverse events
Pregnancy & Lactation
- Potential fetal harm
- Recommendations for pregnant and nursing women
Precautions & Warnings
- Incidence of Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Monitoring of complete blood count for cytopenia
- Risk of pneumonitis
Overdose Effects
- No specific treatment established
- General supportive and symptomatic measures
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store below 30°C
- Protect from light
- Keep out of the reach of children